---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025336"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2026-05-27T12:00:25+00:00"
generated_at: "2026-05-27T12:07:48.057217+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics terminates Wugen license, regains ex vivo rights to HCW9201/9206 at no cost

## Summary
- Company exercised option to terminate exclusive worldwide license from Wugen for ex vivo rights to HCW9201 and HCW9206; regained rights at no cost.
- Retained nonrefundable upfront license fee including 2.2 million shares of Wugen common stock.
- Recent data in Science Advances suggests HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies.
- Company plans to commercialize the reagents through partners focused on CAR-T and NK-cell therapies.

## SEC filing metadata
- accession: 0001493152-26-025336
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2026-05-27T12:00:25+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000149315226025336/0001493152-26-025336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000149315226025336/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025336
- JSON: https://secwatch.observer/filing/0001493152-26-025336.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.